Nusinersen for the treatment of spinal muscular atrophy.

Abstract:

INTRODUCTION:Spinal muscular atrophy (SMA) is an autosomal recessive degenerative neuromuscular disorder characterized by loss of spinal motor neurons leading to muscle weakness. This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, SpinrazaTM) and describes the exciting journey from early ASO clinical trials to regulatory approval of the first ever known effective treatment for SMA. Areas covered: This article reviews the results of the published open label nusinersen studies in infants and children, and briefly covers the preliminary findings of the recently completed but as yet unpublished nusinersen-sham controlled trials, as well as the presymptomatic nusinersen trial known as Nurture. Clinical use of nusinersen is also reviewed. Expert commentary: Collectively, the studies show improvement in motor function across SMA of all types, including SMA type 3. Best motor response was observed with early treatment; presymptomatic treatment prevented disease manifestations. Nusinersen was found to be safe and well tolerated across all age groups studied. Nusinersen has irrevocably altered the natural history of SMA and allowed for the first time children to transition between SMA types. Nusinersen should be considered as standard of care for the treatment of SMA of all types.

journal_name

Expert Rev Neurother

authors

Chiriboga CA

doi

10.1080/14737175.2017.1364159

subject

Has Abstract

pub_date

2017-10-01 00:00:00

pages

955-962

issue

10

eissn

1473-7175

issn

1744-8360

journal_volume

17

pub_type

杂志文章,评审
  • Interferon-beta1b in multiple sclerosis.

    abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.3.227

    authors: Buttmann M,Rieckmann P

    更新日期:2007-03-01 00:00:00

  • Cladribine for multiple sclerosis: review and current status.

    abstract::In the 1990s, cladribine was developed as an adenosine deaminase-resistant nucleoside analog with selective lymphotoxic specificity in the hope that it might become useful in the treatment of some lymphoid neoplasms and autoimmune disorders. Several clinical trials demonstrated very significant effectiveness and safet...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.721

    authors: Sipe JC

    更新日期:2005-11-01 00:00:00

  • Neurostimulation in primary headache syndromes.

    abstract::Neurostimulation therapy involves the use of peripheral or central nerve electrical stimulation approaches for the treatment of medically intractable headache. Currently, for peripheral stimulation the main approach is that of occipital nerve stimulation, while for central stimulation deep-brain approaches with the ta...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.12.1785

    authors: Goadsby PJ

    更新日期:2007-12-01 00:00:00

  • Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.

    abstract::With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.3.357

    authors: Bergamaschi R

    更新日期:2006-03-01 00:00:00

  • Metabolic treatments of migraine.

    abstract::Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavorable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and better tolerated, but they are expensive and may no...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1729130

    authors: Lisicki M,Schoenen J

    更新日期:2020-03-01 00:00:00

  • Microbiota-gut brain axis involvement in neuropsychiatric disorders.

    abstract::Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1638763

    authors: Iannone LF,Preda A,Blottière HM,Clarke G,Albani D,Belcastro V,Carotenuto M,Cattaneo A,Citraro R,Ferraris C,Ronchi F,Luongo G,Santocchi E,Guiducci L,Baldelli P,Iannetti P,Pedersen S,Petretto A,Provasi S,Selmer K,Sp

    更新日期:2019-10-01 00:00:00

  • New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention.

    abstract:INTRODUCTION:Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleedin...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1268053

    authors: Arnao V,Riolo M,Tuttolomondo A,Pinto A,Fierro B,Aridon P

    更新日期:2017-06-01 00:00:00

  • Cardiovascular effects of antipsychotics.

    abstract::There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipid...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.7.829

    authors: Michelsen JW,Meyer JM

    更新日期:2007-07-01 00:00:00

  • Alzheimer's disease: review of current nanotechnological therapeutic strategies.

    abstract::Introduction: Alzheimer's Disease (AD) is a progressive neurodegenerative pathology characterized by the presence of neuritic plaques and neurofibrillary tangles. The most important markers in AD pathology include excessive accumulation of amyloid beta (Aβ42) and phosphorylated tau (P-tau) proteins. One of the possibl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1719069

    authors: Baranowska-Wójcik E,Szwajgier D

    更新日期:2020-03-01 00:00:00

  • Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers.

    abstract::Alzheimer's disease is an age-related dementia and its incidence is rising in developed countries as the population ages. Amyloid plaques and tau-rich neurofibrillary tangles are pathologic hallmarks of the disease. Treatment is symptomatic, consisting of compounds that block enzymatic acetylcholine degradation (acety...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.1.97

    authors: Silverberg GD,Mayo M,Saul T,Carvalho J,McGuire D

    更新日期:2004-01-01 00:00:00

  • New advances in the rehabilitation of CNS diseases applying rTMS.

    abstract::Transcranial magnetic stimulation (TMS) can directly stimulate the CNS, modifying the brain's plasticity to enhance the behavior of the paretic extremities. Studies with low-frequency repetitive TMS (rTMS) on the intact hemisphere and those with high frequencies on the affected hemisphere could increase the speed of m...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.2.165

    authors: Málly J,Stone TW

    更新日期:2007-02-01 00:00:00

  • Craniomandibular muscles, intraoral orthoses and migraine.

    abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.3.371

    authors: Shevel E

    更新日期:2005-05-01 00:00:00

  • Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders.

    abstract::The 10th Global College of Neuroprotection and Neuroregeneration Annual Conference in collaboration with the 6th International Association of Neurorestoratology VI Intercontinental Hotel, Bucharest, Romania, 4-7 April 2013 The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2013.836297

    authors: Sharma HS,Muresanu DF,Sharma A

    更新日期:2013-10-01 00:00:00

  • Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches.

    abstract::Sumatriptan subcutaneous administration is the fastest and most effective of the triptans for relief of acute migraine headache. This occurs even when the patient has already developed symptoms related to central sensitization, a key parameter in determining the effectiveness of these agents. In patients whose migrain...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.41

    authors: Freitag FG

    更新日期:2011-04-01 00:00:00

  • Fingolimod for the treatment of relapsing multiple sclerosis.

    abstract::Fingolimod is the first oral agent approved in the USA for the treatment of relapsing forms of multiple sclerosis. Fingolimod is a sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phosphate receptors on lymphocytes, resulting in a downregulation of the receptor and a reversible sequestration of l...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.193

    authors: Jeffery DR,Markowitz CE,Reder AT,Weinstock-Guttman B,Tobias K

    更新日期:2011-02-01 00:00:00

  • Combination treatments in Alzheimer's disease: risks and benefits.

    abstract::Currently approved medications to treat cognitive deficits in Alzheimer's disease are targeting relatively late neurotransmission alterations and, thus, new approaches are needed to improve the observed modest efficacy. Employing various combinations of existing drugs is one way to achieve this aim. We can attempt to ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.43

    authors: Sobow T

    更新日期:2010-05-01 00:00:00

  • NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age.

    abstract::Since we last addressed the roles of NF-κB and JAK/STAT3 signaling in glioblastoma (GBM) 5 years ago, tremendous strides have been made in the understanding of these two pathways in glioma biology. Contributing to prosurvival mechanisms, cancer stem cell maintenance and treatment resistance, both NF-κB and STAT3 have ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.964211

    authors: Gray GK,McFarland BC,Nozell SE,Benveniste EN

    更新日期:2014-11-01 00:00:00

  • Treating multiple sclerosis with monoclonal antibodies: a 2013 update.

    abstract::The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.13.17

    authors: Deiß A,Brecht I,Haarmann A,Buttmann M

    更新日期:2013-03-01 00:00:00

  • Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.

    abstract::Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with MS and their DMD exposure in four Canadian provinces. Methods: We i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1847085

    authors: Ng HS,Zhu F,Kingwell E,Zhao Y,Yao S,Ekuma O,Svenson LW,Evans C,Fisk JD,Marrie RA,Tremlett H

    更新日期:2021-01-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00

  • Role of the cholinergic system in the pathology and treatment of schizophrenia.

    abstract::Schizophrenia is a devastating psychiatric disorder; the diagnosis probably encompasses a number of illnesses with similar clinical presentations, complicating both treatment and studies into the pathology of the disorder. The development of antipsychotic medications revolutionized treatment for the disorder. However,...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.1.73

    authors: Scarr E,Dean B

    更新日期:2009-01-01 00:00:00

  • Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis?

    abstract::Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.111

    authors: Dennison L,Moss-Morris R

    更新日期:2010-09-01 00:00:00

  • The search for biomarkers in Parkinson's disease: a critical review.

    abstract::Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily presents with features of bradykinesia, rigidity and tremor, and has, as part of its core pathology, the degeneration of dopaminergic neurons in the substantia nigra pars compacta. There is a great need for the development of a reliabl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.12.1841

    authors: Antoniades CA,Barker RA

    更新日期:2008-12-01 00:00:00

  • Pathogenic role of mitochondrial [correction of mitochondral] amyloid-beta peptide.

    abstract::Metabolic dysfunction is one of the early features in Alzheimer's disease (AD) affected brain. Amyloid-beta peptide (Abeta), a major peptide deposited in neuritic plaques, has been considered as an important initiating molecule in the pathogenesis of AD. However, the pathogenic role of Abeta remains to be determined. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.11.1517

    authors: Chen JX,Yan SD

    更新日期:2007-11-01 00:00:00

  • Immunotherapy of neuroblastoma: present, past and future.

    abstract::Neuroblastoma is a neuroectodermal tumor of childhood with poor prognosis and low survival in patients with advanced-stage disease who respond to conventional therapies but unfortunately, often present relapse. Therefore, the search for novel therapeutic strategies is warranted and represents the objective of many inv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.4.509

    authors: Raffaghello L,Pistoia V

    更新日期:2006-04-01 00:00:00

  • New therapeutics in spine metastases.

    abstract::The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.831

    authors: Bilsky MH

    更新日期:2005-11-01 00:00:00

  • Cannabinoids and pain relief.

    abstract::Understanding of the structure and function of the endocannabinoid system is rapidly evolving. Physiological and pharmacological manipulations based on cannabinoid receptors, ligands and endocannabinoids have explained some medicinal attributes of cannabinoids as used across the world for thousands of years. Plant-der...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.1.1.92

    authors: Holdcroft A,Patel P

    更新日期:2001-09-01 00:00:00

  • Promoting productive interactions between parents and physicians in the treatment of children with attention-deficit/hyperactivity disorder.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral condition that impairs functioning throughout childhood and adolescence. Evidence-based guidelines for the treatment of ADHD recommend recognizing ADHD as a chronic condition. The chronic care model for child health emphasizes the need for pro...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.151

    authors: Brinkman WB,Epstein JN

    更新日期:2011-04-01 00:00:00

  • The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.

    abstract::Irreversible disability is the critical long-term consequence of multiple sclerosis (MS). While there are well-established measures for disability in MS, they have limitations that may affect our perception of disease progression either due to the empirical nature of some assessments or the lack of validation with lon...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.869478

    authors: Kieseier BC

    更新日期:2014-01-01 00:00:00

  • Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease.

    abstract::The demographics of aging identify an immediate need for the early diagnosis and development of dementia prevention strategies. Recent neuropathological studies have pointed to the early involvement of the hippocampus and entorhinal cortex in the progression of Alzheimer's disease in the brain. In particular, these st...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.5.831

    authors: Mosconi L,De Santi S,Rusinek H,Convit A,de Leon MJ

    更新日期:2004-09-01 00:00:00